Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DF-003 SAD and MAD in Healthy Subjects
NCT05997641Phase 1Active, not recruiting
- Sponsor
- Drug Farm
- Start
- Sep 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DF-003 in chronic kidney disease (CKD) (4 arms), sponsored by Drug Farm. Primary endpoints: Incidence of Adverse Events up to 83 days and Incidence of Serious Adverse Events up to 83 days. Started Sep 2023; status: active, not recruiting.
02
Drugs
DF-003
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05997641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05997641.